Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals

被引：0
|
作者：
Jagpreet Chhatwal
Tianhua He
Maria A. Lopez-Olivo
机构：
[1] Harvard Medical School,Institute for Technology Assessment, Massachusetts General Hospital
[2] Tsinghua University School of Medicine,Department of General Internal Medicine
[3] The University of Texas,undefined
[4] MD Anderson Cancer Center,undefined
来源：
PharmacoEconomics | 2016年 / 34卷
关键词：
Sustained Virological Response Rate; Telaprevir; Sofosbuvir; Boceprevir; Consolidate Health Economic Evaluation Reporting Standard;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：551 / 567
页数：16
相关论文
共 50 条
  • [31] Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C
    Li, Chunhong
    Liang, Jing
    Xiang, Huiling
    Chen, Haiyan
    Tian, Jie
    MEDICINE, 2020, 99 (48) : E23384
  • [32] The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs
    Roncero, Carlos
    Luis Villegas, Jose
    Martinez-Rebollar, Maria
    Buti, Maria
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (10) : 999 - 1030
  • [33] Hepatitis C virus resistance to the new direct-acting antivirals
    Esposito, Isabella
    Trinks, Julieta
    Soriano, Vicente
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (10) : 1197 - 1209
  • [34] Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C
    Neokosmidis, Georgios
    Protopapas, Adonis A.
    Stogiannou, Dimitrios
    Filippidis, Athanasios
    Tziomalos, Konstantinos
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (01): : 58 - 66
  • [35] Direct-acting antivirals for children and adolescents with chronic hepatitis C
    Indolfi, Giuseppe
    Serranti, Daniele
    Resti, Massimo
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (04) : 298 - 304
  • [36] The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of Chronic Hepatitis C
    Gaetano, John N.
    Desai, Archita P.
    Reau, Nancy
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2012, 4 : 39 - 56
  • [37] Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France
    Djaogol, Tchadine
    Fontaine, Helene
    Baudoin, Mael
    Protopopescu, Camelia
    Marcellin, Fabienne
    Dorival, Celine
    Simony, Melanie
    Petrov-Sanchez, Ventzislava
    Bourliere, Marc
    Delarocque-Astagneau, Elisabeth
    Pol, Stanislas
    Carrat, Fabrice
    Carrieri, Patrizia
    LIVER INTERNATIONAL, 2021, 41 (10) : 2328 - 2340
  • [38] Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan
    Zhuo, Yueran
    Hayashi, Tomoyuki
    Chen, Qiushi
    Aggarwal, Rakesh
    Hutin, Yvan
    Chhatwal, Jagpreet
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [39] IL28B in the Era of Direct-acting Antivirals for Hepatitis C
    Muir, Andrew J.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2013, 47 (03) : 222 - 227
  • [40] Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals
    Mar, Javier
    Ibarrondo, Oliver
    Martinez-Baz, Ivan
    Juanbeltz, Regina
    San-Miguel, Ramon
    Casado, Itziar
    Arrospide, Arantzazu
    Castilla, Jesus
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2018, 110 (10) : 621 - 628
12345